<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088720</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/354/7/19</org_study_id>
    <nct_id>NCT05088720</nct_id>
  </id_info>
  <brief_title>Misoprostol for Management of Women With an Incomplete Miscarriage</brief_title>
  <official_title>Comparative Study Between Two Doses of Misoprostol in Women With Incomplete First-trimester Miscarriage After Misoprostol Treatment: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Miscarriage is defined as the spontaneous loss of a pregnancy before 24 weeks gestation, that&#xD;
      is, before fetal viability. The clinical signs of miscarriage are usually vaginal bleeding&#xD;
      associated with abdominal pain and cramping. The miscarriage is named 'complete' or&#xD;
      'incomplete' according to whether or not tissues are retained in the uterus. If a woman has&#xD;
      minimal bleeding but her cervix is closed, this is known as a 'threatened miscarriage.&#xD;
      However; if the pregnancy is still inside the uterus but the cervix is open, this is&#xD;
      described as an 'inevitable miscarriage', which it will not usually be possible to save the&#xD;
      fetus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the aim of the study is to evaluate 2 doses with misoprostol in Women With Incomplete&#xD;
      First-trimester Miscarriage After Misoprostol Treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a double-blind placebo-controlled randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>a double-blind placebo-controlled randomized trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with complete miscarriage at 1 week</measure>
    <time_frame>7 days</time_frame>
    <description>The number of patients with complete miscarriage at 1 week</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Miscarriage</condition>
  <arm_group>
    <arm_group_label>misoprostol 800 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol 400 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol 800 µg</intervention_name>
    <description>received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually</description>
    <arm_group_label>misoprostol 800 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol 400 µg</intervention_name>
    <description>received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually</description>
    <arm_group_label>misoprostol 400 µg</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation.&#xD;
&#xD;
          -  No known allergy to misoprostol.&#xD;
&#xD;
          -  Women who will be hemodynamically stable.&#xD;
&#xD;
          -  Good access to emergency facilities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with signs of severe infection ( fever &gt; 38°)&#xD;
&#xD;
          -  Women with severe vaginal bleeding&#xD;
&#xD;
          -  Women are known to have allergies to prostaglandins&#xD;
&#xD;
          -  Severe abdominal pain requiring immediate intervention&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women with incomplete missed abortion</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

